Renaissance Technologies
NRIX icon

Renaissance Technologies’s Nurix Therapeutics NRIX Stock Holding History

Renaissance Technologies’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-118,000
Closed -$1.83M – 3503
2026
Q1 		$1.83M Buy
+118,000
New +$1.96M ﹤0.01% 1951
2025
Q4 		– Sell
-184,800
Closed -$1.71M – 3586
2025
Q3 		$1.71M Buy
184,800
+162,900
+744% +$1.69M ﹤0.01% 2174
2025
Q2 		$249K Sell
21,900
-37,600
-63% -$406K ﹤0.01% 3095
2025
Q1 		$707K Buy
+59,500
New +$995K ﹤0.01% 2595
2024
Q4 		– Sell
-246,400
Closed -$5.54M – 3792
2024
Q3 		$5.54M Sell
246,400
-77,600
-24% -$1.76M 0.01% 1383
2024
Q2 		$6.76M Buy
324,000
+144,700
+81% +$2.25M 0.01% 1127
2024
Q1 		$2.64M Buy
179,300
+64,100
+56% +$689K ﹤0.01% 1837
2023
Q4 		$1.19M Buy
115,200
+88,400
+330% +$606K ﹤0.01% 2291
2023
Q3 		$211K Buy
+26,800
New +$245K ﹤0.01% 3074
2023
Q2 		– Sell
-28,900
Closed -$257K – 4160
2023
Q1 		$257K Sell
28,900
-89,800
-76% -$936K ﹤0.01% 3176
2022
Q4 		$1.3M Buy
118,700
+45,400
+62% +$548K ﹤0.01% 2372
2022
Q3 		$955K Sell
73,300
-45,100
-38% -$714K ﹤0.01% 2526
2022
Q2 		$1.5M Buy
118,400
+42,200
+55% +$478K ﹤0.01% 2410
2022
Q1 		$1.07M Buy
+76,200
New +$1.35M ﹤0.01% 2684

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies's NRIX Position: Q2 2026 in Review

Renaissance Technologies sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 118,000 shares — an estimated $1.83M sold.

Renaissance Technologies first reported a position in NRIX in Q1 2022 and held it in 14 quarters. The position peaked at $6.76M in Q2 2024. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Renaissance Technologies reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Renaissance Technologies sold 118,000 Nurix Therapeutics shares in Q2 2026, an estimated $1.83M.
  • Renaissance Technologies first reported a position in Nurix Therapeutics in Q1 2022 and held it in 14 quarters.
  • Renaissance Technologies's Nurix Therapeutics position peaked at $6.76M in Q2 2024.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.